

Venus bags first patent from Canada for Vancoplus

12 September 2012 | Regulatory | By BioSpectrum Bureau

Venus bags first patent from Canada for Vancoplus



New Delhi: Chandigarh-based Venus Remedies, a leading research based global pharmaceutical company secured its first patent from Canada for its novel antibiotic adjuvant entity, Vancoplus. The patent has been granted by the Canadian patent office and is valid up to May 2027. The company is planning to launch the product in Canada within the next two years.

Commenting on this accomplishment, Dr (Mrs) Manu Chaudhary, JMD and director, research, said, "We are really enthusiastic over the receiving of this Canadian patent for Vancoplus, which will prove to be a fertile ground for the success of this product not just commercially but also in terms of catering to the constantly rising *Methicillin Resistant Staphylococcus Aureus* (MRSA) infection rates in Canada."

As per a research report published by Canadian Antimicrobial Resistance Alliance (CARA), the community acquired MRSA cases have increased significantly from 19.5 percent in 2007 to 38.1 percent in 2010. Various studies and surveys conducted in Canada state that almost 40 percent of the MRSA cases have arisen from the community with increase in MRSA infection amongst children and young adults who have no hospital contact or exposure.

Dr Mufti Suhail Sayeed, SVP, Venus Medicine Research Center (VMRC), said that, Vancoplus is an antibiotic adjuvant entity (AAE) constituting Ceftriaxone plus Vancomycin along with an adjuvant, which restricts the production of toxin by MRSA pathogens and is highly effective in combating *Methicillin Resistant Staphylococcus Aureus* (MRSA) along with other advantages of reduced treatment time, cost and adverse effects.

The company has already been marketing Vancoplus successfully in India and few of the merging markets across the globe. Venus Remedies' Baddi facility is already approved as per EU GMP for manufacturing of Vancoplus, which is in line with the Canadian Regulatory authorities to market the drug. Vancoplus is growing with a CAGR of 50 percent since past three years. Apart from Canada, the patent for this product has already been granted by the US, South Africa, New Zealand and Ukraine and Australia.